Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BXJ0
UPID:
C1QT5_HUMAN
Alternative names:
-
Alternative UPACC:
Q9BXJ0; A6NDD3; B0YJ35; Q335M2; Q8N6P2; Q9UFX4
Background:
Complement C1q tumor necrosis factor-related protein 5 plays a pivotal role in the immune system, bridging innate and adaptive immunity. Its involvement in cellular signaling pathways underscores its importance in maintaining homeostasis.
Therapeutic significance:
Linked to Late-onset retinal degeneration, a disorder marked by progressive vision loss, this protein's study could lead to groundbreaking treatments for retinal diseases, highlighting the importance of targeted therapeutic interventions.